Arcturus Therapeutics (NASDAQ:ARCT) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Arcturus Therapeutics (NASDAQ:ARCT) released its earnings results on Thursday. The biotechnology company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.16, FiscalAI reports. The business had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative return on equity of 44.42% and a negative net margin of 317.62%.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• ARCT-810 completed Phase II enrollment and dosing in OTC deficiency, with U.S. and European data expected in Q3 2026 alongside FDA-requested supplementary data and an update on the regulatory path for adult and pediatric development.
• ARCT-032’s Phase II cystic fibrosis study remains on schedule, supported by expanded enrollment in Israel and Turkey; Arcturus expects to decide whether to advance to Phase III in Q4 2026, which would trigger substantial manufacturing and development support from Thermo Fisher.
• Arcturus regained global rights to KOSTAIVE and its broader self-amplifying mRNA vaccine portfolio after ending the CSL Seqirus collaboration. The settlement included a $12 million cash payment and release from approximately $16 million in liabilities, while returning strategic control that could enable commercialization and new partnerships.
• Revenue fell sharply to $3 million in Q2 2026 from $28.3 million a year earlier as the CSL collaboration wound down, while cash declined to $191.5 million from $230.8 million at year-end 2025.
• Management said the company has more than two and a half years of cash runway through year-end 2028, but it will need to balance rare-disease clinical spending with efforts to commercialize or partner the returned vaccine assets.

Arcturus Therapeutics Price Performance

NASDAQ ARCT traded up $1.33 during trading on Friday, reaching $7.41. 1,461,125 shares of the company’s stock traded hands, compared to its average volume of 442,082. Arcturus Therapeutics has a 12-month low of $5.50 and a 12-month high of $24.17. The firm has a market cap of $210.59 million, a price-to-earnings ratio of -2.24 and a beta of 2.39. The company’s 50 day simple moving average is $6.77 and its two-hundred day simple moving average is $7.38.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ARCT. Osaic Holdings Inc. increased its holdings in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 738 shares during the period. BNP Paribas Financial Markets lifted its holdings in Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after buying an additional 2,586 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Arcturus Therapeutics during the 4th quarter valued at $64,000. Intech Investment Management LLC bought a new stake in Arcturus Therapeutics during the 4th quarter valued at $70,000. Finally, CANADA LIFE ASSURANCE Co increased its holdings in shares of Arcturus Therapeutics by 65.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 4,737 shares during the period. 94.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ARCT. Wall Street Zen lowered shares of Arcturus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.